Symbol not found

:CYDY   00:00AM GMT
0.00
0.00 (0.00%)
Other Pre-Announcement

Cytodyn Inc Says Plans To Initiate A Registration-Directed Study Of Leronlimab Monotherapy Indication

Published: 03/05/2021 23:09 GMT
(CYDY) - Cytodyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill Covid-19 Patients Treated With Leronlimab.
Cytodyn Inc - Expects to Refile Its Bla in First Half of Calendar Year 2021.
Cytodyn Inc - Has Been Working Diligently to Refile Its Bla for This Hiv Combination Therapy Since Receiving a Refusal to File in July 2020.
Cytodyn Inc - Plans to Initiate a Registration-directed Study of Leronlimab Monotherapy Indication.